MX360594B - Catalizadores nucleofilicos para enlace de oxima. - Google Patents
Catalizadores nucleofilicos para enlace de oxima.Info
- Publication number
- MX360594B MX360594B MX2014013919A MX2014013919A MX360594B MX 360594 B MX360594 B MX 360594B MX 2014013919 A MX2014013919 A MX 2014013919A MX 2014013919 A MX2014013919 A MX 2014013919A MX 360594 B MX360594 B MX 360594B
- Authority
- MX
- Mexico
- Prior art keywords
- water soluble
- soluble polymer
- carbohydrate moiety
- oxidized carbohydrate
- methods
- Prior art date
Links
- 239000012011 nucleophilic catalyst Substances 0.000 title abstract 2
- 150000002923 oximes Chemical class 0.000 title abstract 2
- 229920003169 water-soluble polymer Polymers 0.000 abstract 4
- 125000000837 carbohydrate group Chemical group 0.000 abstract 3
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 abstract 2
- 230000021615 conjugation Effects 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 150000007857 hydrazones Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Water Supply & Treatment (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647814P | 2012-05-16 | 2012-05-16 | |
| US13/488,043 US8809501B2 (en) | 2009-07-27 | 2012-06-04 | Nucleophilic catalysts for oxime linkage |
| PCT/US2013/041280 WO2013173543A1 (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013919A MX2014013919A (es) | 2015-06-05 |
| MX360594B true MX360594B (es) | 2018-11-09 |
Family
ID=48579473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013919A MX360594B (es) | 2012-05-16 | 2013-05-16 | Catalizadores nucleofilicos para enlace de oxima. |
Country Status (12)
| Country | Link |
|---|---|
| EP (3) | EP4019049A1 (https=) |
| JP (5) | JP6195611B2 (https=) |
| KR (4) | KR102287040B1 (https=) |
| CN (2) | CN109620963B (https=) |
| AU (1) | AU2013204754C1 (https=) |
| BR (1) | BR112014028636B1 (https=) |
| CA (1) | CA2873756C (https=) |
| EA (2) | EA035506B1 (https=) |
| MX (1) | MX360594B (https=) |
| NZ (4) | NZ738844A (https=) |
| SG (3) | SG11201407597XA (https=) |
| WO (2) | WO2013173543A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013204754C1 (en) * | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
| KR20240045351A (ko) * | 2016-11-14 | 2024-04-05 | 노파르티스 아게 | 연골 손상 및 관절염 치료 방법 및 조성물 |
| JP7002036B2 (ja) * | 2016-11-17 | 2022-01-20 | パナソニックＩｐマネジメント株式会社 | 膜電極接合体および固体酸化物形燃料電池 |
| US11786586B2 (en) | 2016-12-23 | 2023-10-17 | Aoa Dx | Carbohydrate structures and uses thereof |
| CN108503901B (zh) * | 2018-04-17 | 2020-07-07 | 哈尔滨工业大学 | 一种抗菌普鲁兰多糖/壳聚糖复合食品包装膜的制备方法 |
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| MX2021008797A (es) | 2019-01-23 | 2022-01-31 | Regeneron Pharma | Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7). |
| US11865134B2 (en) | 2021-02-26 | 2024-01-09 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors |
| EP4491603A4 (en) | 2022-03-07 | 2026-03-11 | Kaneka Corp | PROCESS FOR PRODUCING A GRANULAR COMPOSITION CONTAINING GLUTATHIONE |
| WO2025133203A1 (en) * | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Compounds and methods for a long-lasting pam |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54113492A (en) | 1978-02-24 | 1979-09-05 | Sanyo Chem Ind Ltd | Preparation of glucoprotein derivative |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| CA2124690C (en) | 1992-10-02 | 2007-09-11 | Thomas Osterberg | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| WO1994028024A1 (en) * | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| US6531298B2 (en) | 1997-07-21 | 2003-03-11 | The University Of North Carolina At Chapel Hill | Factor IX antihemophilic factor with increased clotting activity |
| US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| DE60116137T2 (de) | 2000-05-16 | 2006-08-24 | Lipoxen Technologies Ltd. | Derivatisierung von proteinen in wässrigem lösungsmittel |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| EP1446438A2 (en) | 2001-11-07 | 2004-08-18 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
| BR0314227A (pt) | 2002-09-11 | 2005-10-25 | Fresenius Kabi De Gmbh | Derivados de amido de hidroxialquila |
| PL1620118T3 (pl) | 2003-04-08 | 2014-11-28 | Yeda Res & Dev | Leki odwracalnie pegylowane |
| PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
| BRPI0412671A (pt) * | 2003-08-08 | 2006-10-03 | Fresenius Kabi De Gmbh | conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima |
| EP1654290B1 (en) | 2003-08-12 | 2019-03-13 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| CN1897812B (zh) | 2003-12-03 | 2011-08-17 | 生物种属学股份公司 | 糖聚乙二醇化的粒细胞集落刺激因子 |
| EP3184551A1 (en) | 2004-08-12 | 2017-06-28 | Lipoxen Technologies Limited | Sialic acid derivatives |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| CN101163506B (zh) | 2004-12-27 | 2012-09-26 | 巴克斯特国际公司 | 聚合物-von Willebrand因子偶联物 |
| HUE025208T2 (en) | 2005-06-16 | 2016-03-29 | Nektar Therapeutics | Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| WO2008025856A2 (en) | 2006-09-01 | 2008-03-06 | Novo Nordisk Health Care Ag | Modified glycoproteins |
| PT2101821E (pt) * | 2006-12-15 | 2014-10-03 | Baxter Int | Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo |
| GB0908393D0 (en) * | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
| ES2597954T3 (es) * | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
| JP5909755B2 (ja) * | 2009-07-27 | 2016-04-27 | リポクセン テクノロジーズ リミテッド | 非血液凝固タンパク質の糖ポリシアル酸化 |
| TR201908836T4 (tr) * | 2010-07-30 | 2019-07-22 | Baxalta GmbH | Oksim bağına yönelik nükleofilik katalizörler. |
| KR101560541B1 (ko) * | 2012-04-13 | 2015-10-19 | 아우토리브 디벨롭먼트 아베 | 에어백 모듈과 스티어링 휠의 조립체 |
| AU2013204754C1 (en) * | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
-
2013
- 2013-04-12 AU AU2013204754A patent/AU2013204754C1/en active Active
- 2013-05-16 NZ NZ738844A patent/NZ738844A/en unknown
- 2013-05-16 SG SG11201407597XA patent/SG11201407597XA/en unknown
- 2013-05-16 CA CA2873756A patent/CA2873756C/en active Active
- 2013-05-16 WO PCT/US2013/041280 patent/WO2013173543A1/en not_active Ceased
- 2013-05-16 SG SG10201701780RA patent/SG10201701780RA/en unknown
- 2013-05-16 KR KR1020217009701A patent/KR102287040B1/ko active Active
- 2013-05-16 EP EP21214357.2A patent/EP4019049A1/en active Pending
- 2013-05-16 JP JP2015512831A patent/JP6195611B2/ja active Active
- 2013-05-16 NZ NZ738846A patent/NZ738846A/en unknown
- 2013-05-16 KR KR1020207013096A patent/KR102237306B1/ko active Active
- 2013-05-16 CN CN201811295900.8A patent/CN109620963B/zh active Active
- 2013-05-16 WO PCT/US2013/041300 patent/WO2013173557A1/en not_active Ceased
- 2013-05-16 EP EP13728026.9A patent/EP2849795B1/en active Active
- 2013-05-16 KR KR1020147035113A patent/KR102110622B1/ko active Active
- 2013-05-16 BR BR112014028636-1A patent/BR112014028636B1/pt active IP Right Grant
- 2013-05-16 KR KR1020217024432A patent/KR102326360B1/ko active Active
- 2013-05-16 MX MX2014013919A patent/MX360594B/es active IP Right Grant
- 2013-05-16 EA EA201790935A patent/EA035506B1/ru not_active IP Right Cessation
- 2013-05-16 EP EP13724491.9A patent/EP2849794A1/en not_active Withdrawn
- 2013-05-16 CN CN201380037823.5A patent/CN104487095B/zh active Active
- 2013-05-16 EA EA201492115A patent/EA028186B9/ru not_active IP Right Cessation
- 2013-05-16 NZ NZ701945A patent/NZ701945A/en unknown
- 2013-05-16 SG SG10201911328QA patent/SG10201911328QA/en unknown
- 2013-05-16 NZ NZ724828A patent/NZ724828A/en unknown
-
2017
- 2017-06-01 JP JP2017109323A patent/JP6560712B2/ja active Active
-
2019
- 2019-02-05 JP JP2019018663A patent/JP6711935B2/ja active Active
-
2020
- 2020-04-03 JP JP2020067396A patent/JP7014844B2/ja active Active
-
2021
- 2021-12-29 JP JP2021215385A patent/JP7304402B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX346271B (es) | Catalizadores nucleofílicos para enlace de oxima. | |
| NZ701945A (en) | Nucleophilic catalysts for oxime linkage | |
| MX2012001207A (es) | Conjugados proteicos de coagulacion sanguínea. | |
| NZ611618A (en) | Battery operated solar charged pump kit utilizing an inline submersible pump | |
| EA201390940A1 (ru) | Материалы и способы конъюгирования водорастворимого производного жирной кислоты с белком | |
| EP4279512A3 (en) | Cytotoxicity-inducing therapeutic agent | |
| HK1217720A1 (zh) | 选择性递送分子及使用方法 | |
| WO2013019681A3 (en) | Selective delivery molecules and methods of use | |
| EP4406612A8 (en) | Anti-cd70 antibody drug conjugates | |
| EA032867B9 (ru) | Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты | |
| EP3093029A8 (en) | Blood coagulation protein conjugates | |
| AU2011274619A8 (en) | miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway | |
| WO2013072813A3 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| WO2012009406A3 (en) | Gold particles and methods of making and using the same in cancer treatment | |
| HK1204326A1 (en) | Enediyne compounds, conjugates thereof, and uses and methods therefor | |
| WO2012170776A3 (en) | Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy | |
| WO2012138694A3 (en) | Compositions comprising saccharide binding moieties and methods for targeted therapy | |
| EP4458859A3 (en) | Conjugate of anti-cdh3 (p-cadherin) antibody and drug | |
| NZ610891A (en) | Cd89 activation in therapy | |
| WO2012019132A3 (en) | Anaplastic lymphoma kinase in kidney cancer | |
| PH12018501174A1 (en) | Factor viii with extended half-life and reduced ligand-binding properties | |
| EA202090685A1 (ru) | Нуклеофильные катализаторы для оксимного связывания | |
| 胡培君 | What Can We Learn from DFT Calculations in Heterogeneous Catalysis? | |
| 周霜 | Functional Discourse Analysis of Twitter News | |
| 冯静 et al. | A NOVEL PENTABODY: A POTENTIAL APPLICATION IN DIAGNOSIS OF AVIAN INFLUENZA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: BAXALTA INCORPORATED |
|
| FG | Grant or registration |